BPC-157 and TB-500: The 'Wolverine' Blend Explained

The BPC-157 and TB-500 blend, nicknamed the Wolverine blend in research circles, combines two peptides that have each been studied for tissue repair in animal models: BPC-157, a stable 15-amino-acid fragment derived from a gastric protein, and TB-500, a synthetic fragment of the actin-binding protein thymosin beta-4. They are paired because the literature suggests they act on different parts of the repair process. Neither compound holds an MHRA marketing authorisation, human evidence remains limited, and in the UK both are supplied strictly as research chemicals.

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a pentadecapeptide, meaning a chain of 15 amino acids, whose sequence corresponds to a fragment of a protein found in human gastric juice. It was characterised in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, whose group has published the great majority of the literature on it since. It is notable among peptides for being stable in gastric acid, which is unusual and is part of why it attracted early interest.

The animal work is extensive and covers a striking range of tissues. Staresinic and colleagues reported in the Journal of Orthopaedic Research in 2003 that BPC-157 accelerated healing of a transected Achilles tendon in rats and stimulated tendon cell growth in vitro. Chang and colleagues in the Journal of Applied Physiology in 2011 described increased tendon fibroblast outgrowth, survival and migration in the presence of the peptide. Other papers from the Zagreb group report effects in rat models of muscle injury, ligament injury, bone defects, gastric ulcers and various vascular lesions.

Mechanistically, the proposed actions include modulation of the nitric oxide system, upregulation of growth hormone receptor expression in tendon fibroblasts, and promotion of angiogenesis via VEGF-related pathways. These are hypotheses drawn largely from rodent data, and they have not been confirmed in controlled human studies.

What is TB-500?

Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein first isolated from calf thymus by Allan Goldstein and colleagues in 1981. Its best-established biological role is sequestering monomeric actin, the building block of the cell cytoskeleton, which places it at the centre of cell migration and shape change. TB-500 is the name used in the research market for a synthetic peptide based on Tβ4, most commonly the short segment containing the actin-binding domain (the LKKTET motif), though some material sold as TB-500 is the full-length protein.

The research on Tβ4 itself is broader and further advanced than that on BPC-157. Malinda and colleagues reported accelerated dermal wound healing in rats in 1999. Bock-Marquette and colleagues published in Nature in 2004 that Tβ4 promoted cardiac cell migration and survival after experimental myocardial infarction in mice. Sosne and colleagues have studied Tβ4 in corneal wound healing. The compound has reached human trials: RegeneRx Biopharmaceuticals has run phase 2 studies of a Tβ4 eye drop for dry eye disease and neurotrophic keratopathy, and a topical gel for epidermolysis bullosa, with mixed results and no marketing authorisation granted anywhere to date.

Why BPC-157 and TB-500 are combined

The rationale for the Wolverine blend comes from the different pictures painted by the two literatures. BPC-157 is most often described as acting locally on the injured tissue: on tendon cells, on blood vessel formation at the site, and on growth-factor receptor expression. Tβ4 is described as a more systemic signal, promoting the migration of cells such as keratinocytes, endothelial cells and cardiac progenitors into a wound and reducing inflammation there.

Researchers interested in soft-tissue repair have therefore paired them on the hypothesis that a local repair signal and a cell-migration signal might be complementary. It should be said plainly that this is a hypothesis. There is no peer-reviewed controlled study, in animals or humans, that tests the combination against either peptide alone. The blend exists because the individual literatures are suggestive, not because the combination has been proven.

What the research shows: key studies at a glance

A useful pattern emerges from the table. Almost all of the BPC-157 evidence comes from one research group and from rodents, while the Tβ4 evidence is wider in origin but relates to the full protein, not necessarily to the fragment sold as TB-500. Both points matter when weighing how far the results generalise.

Human evidence: what exists and what does not

For BPC-157, the honest summary is that there are no published, peer-reviewed, randomised controlled trials in humans. The Zagreb group has referred to early clinical work in inflammatory bowel disease, and small observational reports have appeared, but nothing that would meet the standard a regulator requires. Systematic reviews published in the last few years consistently conclude that the human evidence base is insufficient to draw conclusions about efficacy or safety.

For Tβ4, there are completed human trials, which is a meaningful difference, but they concern ophthalmic and dermatological formulations of the full-length protein for specific indications. They do not tell us about the short TB-500 fragment, about other routes, or about musculoskeletal outcomes. A 2026 scoping review of Tβ4 and TB-500 in tissue healing noted the same gap between the animal data and the available human evidence.

UK legal status and anti-doping

In the UK, neither BPC-157 nor TB-500 holds a marketing authorisation from the MHRA, and neither is controlled under the Misuse of Drugs Act 1971. Both are legal to buy, sell and possess as research chemicals. What is not lawful is supplying either peptide for human medicinal use, which falls under the Human Medicines Regulations 2012. That is the line that separates a research supplier from an unlicensed pharmacy, and it is why every reputable UK vendor labels these products for laboratory research only.

Anyone involved in sport should note that both compounds sit on the World Anti-Doping Agency Prohibited List. Thymosin beta-4 and its derivatives, including TB-500, have been listed under section S2 (peptide hormones, growth factors and related substances) for well over a decade. BPC-157 was named explicitly under section S0 (non-approved substances) from the 2022 list. Both are prohibited at all times, in and out of competition.

The Calibre Wolverine pen: what is in it and how it is tested

The Calibre Wolverine High Strength pen contains 20 mg of BPC-157 and 20 mg of TB4 in a single pre-filled, precision-made cartridge. Supplying a blend rather than two separate products means a researcher working with the combination has one batch, one certificate and one concentration to record, rather than reconciling two.

Each batch is sent to Janoshik Analytical for independent HPLC purity and mass-spectrometry identity testing, with a target of above 99% purity for each component. The report is published on our COA page with its verification ID. Testing a two-component blend is more demanding than testing a single peptide because both compounds need to be resolved on the chromatogram and both masses confirmed, which is one reason a verifiable third-party report matters more for blends than for single-compound products.

Related Calibre products that also contain BPC-157 and TB4 include the Glow pen (GHK-Cu 50 mg, TB4 10 mg, BPC-157 10 mg) and the Klow pen, which adds KPV to the same base. For batch-specific certificates or questions about any of them, contact us by WhatsApp, Telegram or email at sales@calibre-pens.co.uk.

Summary

The BPC-157 and TB-500 Wolverine blend brings together two peptides with substantial animal literature on tissue repair and very little controlled human data. The pairing rests on a plausible but untested hypothesis that local repair and cell-migration signals are complementary. In the UK the blend is a legal research chemical with no MHRA authorisation, prohibited in sport, and available from Calibre as an independently tested pre-filled pen for laboratory use.